Table 2.

PET and pathology findings for nineteen patients

Patient	Age at death	PiB	Tau	Years between scan - death	Primary pathology	NIA-AA AD level	Braak stage	Thal phase
1	73.7	1.73	1.22	1.3	PSP	Int	IV	A2 (Thal 3)
2	52.9	1.23	1.21	1.5	CBD	Not	IV	A0
3	77.8	1.27	1.09	3.4	PSP	Not	I	A0
4	68.4	1.41	1.26	0.9	CBD	Not	II	A0
5	92.7	1.81	1.24	5.6	CBD	Low-int	IV	A1 (Thal 1/2)
6	59.6	1.23	1.14	0.8	CBD	Not	IV	A0
7	84.6	1.93	1.23	2.6	PSP	Low-int	III-IV	A1 (Thal 1/2)
8	78.1	1.67	1.3	5.3	PSP	Int	IV-V	A2 (Thal 3)
9	72.3	1.37	1.22	2.5	PSP	Unknown	III	unknown
10	60.0	1.43	1.18	1.7	FTLD-TDP1	Low-int	III	A1 (Thal 1/2)
11	57.5	1.19	1.26	2.9	FTLD-TDP1	Not	I	A0
12	64	1.36	1.15	4.8	Pick’s Disease	Low	IV-V	A1 (Thal 1/2)
13	61	1.32	1.20	2.4	CBD	Int	IV-V	A1 (Thal 1/2)
14	64	1.16	1.16	2.2	Mixed 3R-4R frontotemporal tauopathy	Not	I	A0
15	87.1	1.37	1.29	4	GGT type1	Low	II	A2 (Thal 3)
16	77.8	1.8	1.11	4	PSP	Low	II	A2 (Thal 3)
17	83.7	1.34	1.2	0.8	PSP	Not	III	A0
18	86.7	1.33	0.96	4.9	PSP	Int	IV	A2 (Thal 3)
19	74	1.93	1.15	3.9	CBD	Low	II	A2 (Thal 3)

¹These patients with FTLD-TDP also had genetic progranulin mutations, as well as executive dysfunction and mild behavioral changes [3].

PiB – Pittsburgh Compound B, NIA-AA – National Institute on Aging-Alzheimer’s Association, PSP – progressive supranuclear palsy, CBD – corticobasal degeneration, FTLD-TDP – frontotemporal lobar degeneration tar DNA binding protein 43, GGT – globular glial pathology